MobiHealth News March 3, 2022
Emily Olsen

Also: Rupa Health raised $20 million for its lab test platform and CancerIQ scooped up $14 million in Series B funding.

Drug discovery startup ArrePath announced Thursday it has raised $20 million in a seed funding round led by the Boehringer Ingelheim Venture Fund, Insight Partners and Innospark Ventures.

Other participants in the round include Viva BioInnovator, Arimed Capital, PTX Capital and Nor’easter Ventures. The company, which focuses on developing new types of anti-infective drugs to best antimicrobial resistance, plans to use the investment to support its machine learning-based drug discovery platform.

ArrePath also appointed Dr. Lloyd Payne as president and CEO. Payne most recently served as executive vice president, head of anti-infectives, at German drug discovery company Evotec.


Today's Sponsors

Institute for Healthcare Improvement
Crossover Health

Today's Sponsors

Patient Bond

Today's Sponsor


Topics: Digital Health, Investments, Technology, Trends
Waltz Health raises more than $35M for drug cost marketplace and more digital health fundings
Unlearn raises $50M for clinical trial digital twins and more digital health fundings
Tech-backed PBM SmithRx scores $20M and more digital health fundings
Q1 2021 Digital Health Startups Set New Investment Record, Led by On-demand Healthcare, Population Health Management and R&D Tech for Pharma
Health tech funding snapshot—Telehealth startup Kry banks $316M; SoftBank backs AI drug discovery Exscientia